Kornimate/medical-research-clean huggingface dataset:
gut microbiota and immune recovery

Conditions: HIV-1-infection

Summary: to explore whether gut microbiota would impact cd4 t cells recovery in hiv-infected patients on antiretroviral therapy (art). we prospectively enroll patients initiate art and collect their fecal at followup for one year.


Eligibility criteria:
inclusion criteria: * confirmed hiv infection * antiretroviral therapy naive * cd4 t cell counts\<350cells/mm3 * agree to participate exclusion criteria: * don't want to start antiretroviral therapy * cocurrent cancer or opportunistic infection * liver diseases * received antibiotics within four weeks of enrollment
municipality-based post-discharge follow-up visits

Conditions: Frailty; Readmission; Transition; Primary Care

Summary: the purpose of this study is to determine whether discharge follow-up visit by primary physician and community-based nurse affects the risk of early re-hospitalisation among high risk older people discharged from a medical ward.


Eligibility criteria:
inclusion criteria: * patient geography (the participant live in; holbæk kommune, odsherred kommune or kalundborg kommune.) * discharged from medical ward holbæk sygehus. * frailty (rated by following criterion: dementia or a minimum of two of the following conditions; two or more hospitalisations within 12 month prior to follow up, los of physical function, treatment of two or more concurrent medical and/or surgical conditions, psychiatric disease, multi-pharmacy of more than 6 prescription medication, suspicious of congenital disturbances, substance abuse problem, disadvantaged social network, need for increasing home care following index hospitalization.) exclusion criteria: * not discharged to home (if the patient are not discharged to home.) * no written consent (if the patient does not wish to participate / written consent are not signed.)

Keywords: frailty readmission transition discharge primary care
acceptability and effectiveness of household water treatment in reducing diarrhea among under five children

Conditions: Acute Diarrhoea

Summary: the millenium development goals (mdgs) call for reducing by half the proportion of people without sustainable access to safe drinking water. this goal was adopted in large part because safe drinking water has been seen as critical to fighting diarrheal disease. source protection is considered the main intervention area to achieve this goal. however, research worldwide that has shown that even drinking water which is safe at the source is subject to frequent and extensive fecal contamination during collection, storage and use in the home. this contamination is through the introduction of cups, dippers or hands, contamination by flies, cockroaches, and rats. even piped water supplies of adequate microbial quality can pose infectious disease risks if they become contaminated due to unsanitary collection, storage conditions and practices within households. to reduce this problem, point-of-use water treatment has been advocated as a means to substantially decrease the global burden of diarrhea and to contribute to the mdgs. however, research indicates that there are many unanswered questions around household water treatment (hwt) that require small or medium scale epidemiological studies and randomized controlled trials, especially with regard to effectiveness, acceptability and identifying suitable target populations. some of the most urgent questions to be resolved are:(1) how much of the currently cited disease reduction of hwt is due to bias? (2) what is the effect of hwt on nutritional status (weight gain and growth)?(3) at which populations should hwt be targeted? (4) is it acceptable and sustainable in poor communities where the risk of diarrheal disease is high. hypothesis: do household water treatment with chlorine reduce diarrhea among underfive children? hypothesis: do household water treatment with chlorine acceptable in the community?


Eligibility criteria:
inclusion criteria: * all children under five years of age in the randomly selected clusters of kersa district exclusion criteria: * seriously sick children in the randomly selected clusters of kersa district

Keywords: three or more loss stools in 24 hours
circadian and seasonal variation in acute myocardial infarction

Conditions: Myocardial Infarction

Summary: circadian and seasonal variation in acute myocardial infarction .

circadian and seasonal variation in acute myocardial infarction and relation between circadian rhythm and seasonal variations with biological and physiological markes of normal human being.

Eligibility criteria:
inclusion criteria: * 1.all patients above (16) years old 2.complaint occur during acute climate changes exclusion criteria: * 1.patients below 16 years old 2.complaint during normal climate
study of at-752 in patients with dengue infection

Conditions: Dengue Fever

Summary: the phase 2 study will be conducted in adult patients with confirmed dengue infection and will investigate safety, pk, and pharmacodynamics (pd) in this population. the study will be conducted in several dosing cohorts to enable dose selection for subsequent trials


Eligibility criteria:
key inclusion criteria: * 18-55 years of age at time of screening * fever ≥38°c (or feeling feverish) with onset during the previous 48 hours * live/work in or recent travel to dengue endemic area * positive test confirming dengue (denv) on a ns1 antigen test or reverse transcription-polymerase chain reaction (rt-pcr) assay * negative rapid diagnostic test result for coronavirus (sars-cov-2) and influenza a and b key exclusion criteria: * pregnant, plans to become pregnant within 90 days of screening, or breast feeding. * has previously received any investigational or approved vaccine for dengue * previous history of hiv, chronic hepatitis b infection, or current hepatitis c infection (from medical history) * use of any antiviral drug within 30 days or within 5 half-lives of the active drug or metabolite (for long-acting antivirals) * current use of anticoagulant or antiplatelet drugs or documented medical history of bleeding disorders * current use of medications for treatment of inflammatory bowel disease or documented medical history of chronic gastrointestinal disease including inflammatory bowel disease * immunocompromised due to use of immunosuppressive drugs including systemic corticosteroids (inhaled or topical corticosteroids are allowed) or any current disease or condition * evidence of severe dengue disease * confirmed or suspected coronavirus (sars-cov-2) infection or contact with patients with confirmed sars-cov2 infection within 7 days prior to screening * other clinically significant medical conditions or laboratory abnormalities, as described in the protocol.

Keywords: dengue vector borne disease infections virus disease viral rna virus hemorrhagic fevers
prognosis of behavioral addiction in parkinson's disease

Conditions: Addiction

Summary: our hypothesis is that the conventional treatment of behavioral addiction in parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy. our goal is to describe the natural history of behavioral addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 30 years * parkinson's disease according to the criteria of ukpdsbb * time evolution of the top disease or equal to 5 years exclusion criteria: * lack of parkinson's disease and atypical parkinsonism * patient not previously included in pd-badge

Keywords: parkinson disease behavioral addiction akinéto-rigid syndrome dopamine agonist
a study of mycobacterium w in combination with paclitaxel plus cisplatin in advanced non small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to determine whether mycobacterium w in combination with paclitaxel plus cisplatin are effective in advanced non small cell lung cancer.

non-small cell lung cancer (nsclc) accounts for 75% of all lung cancers. majority of patients of nsclc patients are stage iiia or iiib patients are suitable for radiotherapy, which could not improve the survival rates of 5-10%. this study proposed mycobacterium w (heat killed) in combination chemotherapy of cisplatin and paclitaxel along with radiotherapy for adjuvant therapy management of nsclc in controlled clinical trial, which may prove the efficacy, better survival rate and quality of life.

Eligibility criteria:
inclusion criteria: * ability to understand and the willingness to sign a written informed consent document. * histologically or cytologically confirmed non-small cell cancer, stage iiib or iv. * age should be 18 years or above. * ecog should be in 0-1 range. * absolute neutrophil count ≥ 1,00,000/mm3 * hemoglobin ≥ 9.0g/dl * ast and alt ≤ 2.5 times upper limit of normal (uln)range of institution (5times uln if liver metastasis present). * bilirubin not greater than 1.5 times uln range of institution (3 times uln if liver involvement). * creatinine ≤ upper limit of normal (uln) range of institution. * negative pregnancy test for women of child bearing potential prior to entry into the trial. exclusion criteria: * patient who have cytotoxic chemotherapy or radiotherapy prior to entering the study * patient with systematic brain metastasis. * history of allergic reaction attributed to paclitaxel, cisplatin or mycobacterium w or any of their ingredients. * pregnant women or nursing women. * uncontrolled intercurrent illness that would limit compliance with study requirements. * hiv positive patients. * previous splenectomy.

Keywords: nsclc
p1101 and anti-pd1 for after curative surgery of hepatitis b-related hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the main purpose of this trial is to evaluate the safety of the new adjuvant treatment of curative hcc, or the treatment of long-acting interferon p1101 alone, or the use of long-acting interferon p1101 and subsequent treatment of anti-pd1, and any efficacy in reducing the recurrence rate of patients after surgery.

secondary end-point: p1101 and anti-pd1 sequential therapy on hepatitis b (especially on hbsag).

Eligibility criteria:
inclusion criteria: * subject with hcc who meet the following criteria 1. subjects diagnosed as having typical hcc on dynamic ct, or dynamic mri performed within 8 weeks before surgery, or subjects who diagnosed hcc by pathology after surgery resection; 2. subjects with the primary occurrence hcc ; 3. subjects with the hcc related to hepatitis b virus (hbv) ; * subject who have undergone surgical liver reaction within 8 weeks prior to study entry. * subjects showing a complete cure shows no findings suggestive of recurrence or remnant. ; * subject who are able to begin treatment with the study drug within 12 weeks after liver surgery resection. ; * subjects confirmed of satisfying the following conditions based on the screening performed at enrollment: positive for hbsag/ undetectable hbv dna, with or without current anti hbv treatment/ grade a on child-pugh classification; * normal fundoscopic examination by ophthalmologist at screening; * ecog 0 to 1 ; exclusion criteria: * subjects positive for anti-hcv ; * subjects showing vascular invasion of hcc on imaging diagnosis ; * subjects who have uncontrolled hypertension; * subjects with a history of pneumonitis or interstitial lung disease . cardiac arrest . an active infection requiring therapy .; * diabetes mellitus with hba1c ≥ 7.4% with insulin treatment;

Keywords: p1101 anti-pd1 hcc hepatocellular carcinoma
anaesthetic and pediatric living related liver transplantation

Conditions: Liver Transplantation; Children

Summary: to study the effect of different anaesthetic methods on pediatric neurocognitive development and cerebral injury during pediatric living related liver transplantation .

since the 1960 s, with the successful development of liver transplantation, it has become an important method for the treatment of patients with end-stage liver disease.biliary atresia1 is the most frequent causes of pediatric end-stage liver disease,.the morbidity of congenital biliary atresia is 1/8000-18, 0002 ,which influence the patients' overall growth and development situation. the rising of living donor liver transplantation has provide children with the chance of a timely treatment since the 1980 s, it is no doubt that pediatric liver transplantation is facing with many complications, including the most importance of neurocognitive development .now the researches of neurological complications is less .according to statistics, the incidence of neurological complications after pediatric liver transplantation was 8% - 46% . so it is necessary to research the neurological complications and brain protection strategy .previous studies have studied that some anaesthetic have uncertain affect on the development of children.

Eligibility criteria:
inclusion criteria: * children with end-stage liver disease children with biliary atresia exclusion criteria: * pre-existing cerebral disease second liver transplantation

Keywords: propofol neurocognitive disorders liver transplantation pediatrics brain injuries
lacosamid-i.v.-register

Conditions: Epilepsy With Partial Onset Seizures With or Without Secondary Generalization

Summary: lacosamide is a new antiepileptic drug (aed) marketed as vimpat with three different formulations, tablets, oral syrup and a solution for intravenous infusion. lacosamide is approved as adjunctive therapy in epilepsy patients with partial onset seizures with or without secondary generalization. the i.v. solution is used in patients in which oral administration is not possible or adequate. bioequivalence with oral tablets and safety could be demonstrated in healthy volunteers and in patients switched from tablets to lacosamide i.v. solution. a recently published study demonstrates the feasibility of single loading doses up to 300 mg. the aim of this lacosamide i.v. registry is to collect systematically data on the safety, tolerability and administration procedures when lacosmide i.v. is used in routine daily clinical practice, mainly in hospitals. these data will help treating physicians to optimize the use of lacosamide i.v. in clinical routine.


Eligibility criteria:
inclusion criteria: * before any data are collected for any patient in this registry an ehtical committee must be notified of the registry and written data consent must be properly executed and documented exclusion criteria:

Keywords: oral administration of lacosamide is not possible or adequate
assessment of the impact of acquisition time, respiratory gating and new qclear reconstruction modalities on the quantification of dosimetry in selective internal radiotherapy

Conditions: Carcinoma, Hepatocellular

Summary: post-processing of positron emission tomography (pet) acquired images, performed following radioembolization treatment with microspheres at 90y in hepatocellular carcinoma patients, is subject to changes commercialized by general electric : respiratory motion correction, specific reconstruction algorithms. we propose to test the possible combinations of these reconstruction parameters to determine which ones to apply for an optimal quality exam with the shortest scan time possible


Eligibility criteria:
inclusion criteria: * patient with hepatocellular carcinoma * with radioembolization treatment decided * over the age of 18 exclusion criteria: * radiembolization not possible * acquisition of pet/ct imaging at 90y not possible
observational study to evaluate ventral incisional hernia repair using a biologic mesh (cook biodesign)

Conditions: Ventral Incisional Hernia

Summary: the purpose of this study is to evaluate the efficacy of the cook biodesign mesh for the repair of complex ventral incisional hernias. using materials to reinforce tissue defects is indicated as standard of care for this type of surgery. the cook biodesign mesh is currently fda-approved for implantation to reinforce soft tissues where weakness exists, but the investigators would like to collect additional follow-up information to continue to assess the durability of the repair after placement of the hernia mesh. this follow-up would include the collection of information about complications such as infections and seromas (collections of fluid around the surgery site), as well as hernia recurrence and quality of life questionnaires. patients who qualify to take part in this study have been diagnosed with a ventral incisional hernia and will have been scheduled for a surgical hernia repair. this surgery will be an "open" surgical procedure and reinforcing your tissue with material is indicated for this type of hernia repair.

prior to their scheduled surgery, the patient will be consented and will complete a brief quality of life survey. they will also be asked some questions about their medical history that pertain to the study, such as current/ past abdominal infections and surgeries, history of the hernia, comorbidities, etc. during the surgery, some key data points will be recorded by the research coordinator, such as time of surgery, type of case, size of mesh used, size of the hernia defect, technique used, type of sutures used, etc. the mesh will be placed either retrorectus or intraperitoneally, after the component separation is complete. the mesh will not be used as a "bridge," and the fascial layers will be closed completely. the research staff may photograph the repair of an enrolled patient's hernia during their treatment and will supply a copy of the photograph to cook medical, inc. if the sponsor's review is requested. any photograph taken for research purposes will be kept in a password-protected, encrypted database separate from any patient identifying information.

Eligibility criteria:
inclusion criteria: * patients undergoing a ventral incisional hernia repair with mesh * age range between 18 and 80 years old exclusion criteria: * patients currently enrolled in a clinical trial. * patients with a bmi over 40 * patients in whom the fascial layers cannot be closed or in whom "bridging" would be used * patients with a current abdominal abscess or infection * patients with healing disorders * pregnant women

Keywords: hernia repair ventral incisional hernia biologic mesh hernia graft
efficacy of nov-002 in combination with carboplatin in chemotherapy-resistant ovarian cancer

Conditions: Ovarian Cancer

Summary: the purpose of this trial is to determine the tumor response rate of nov-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

the purpose of this research study is to learn if adding nov-002 to the chemotherapy drug carboplatin works in treating ovarian cancer. platinum containing drugs such as carboplatin are the standard treatment for ovarian cancer, and are effective for many women. however, in many women the cancer eventually stops responding to the chemotherapy (becomes resistant). the active part of nov-002 is a substance made by the body that is involved in many chemical reactions in cells. nov-002 does not directly kill cancer cells, but previous research has shown that it may make cancer cells more likely to be killed by chemotherapy drugs. specifically, it may help platinum chemotherapy kill cancer that has become resistant to platinum chemotherapy. previous trials have also shown that patients receiving nov-002 in addition to carboplatin may have tolerated chemotherapy better than those who received chemotherapy alone. nov-002 has been used in other research studies on various types of cancer. it is approved for use in russia. it is not approved by the us food and drug administration (fda) for use outside of research studies. in this research study, the investigators are looking to see if adding nov-002 to the chemotherapy drug carboplatin works in treating ovarian cancer in women whose cancer has stopped responding to carboplatin chemotherapy alone.

Eligibility criteria:
inclusion criteria: * histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer * ecog 0-1 * platinum resistant or refractory disease defined as progressive disease within 6 months of completing or while receiving their last platinum containing regimen * measurable disease exclusion criteria: * history of other malignancies within 2 years except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, incidental stage i endometrial cancer, basal or squamous cell skin cancer * major surgery within 2 weeks of study entry * history of anaphylactic shock with prior platinum chemotherapy * known history of central nervous system (cns) metastases unless subject has had treatment with surgery or radiation therapy and is neurologically stable * treatment with more than 3 lines of chemotherapy * chronic use of systemic corticosteroids

Keywords: platinum resistant tumors of ovarian origin
dental emergencies among patients of the health care access center at the university hospital of nancy

Conditions: Community Dentistry; Emergencies

Summary: the dental health care access center at the university hospital of nancy opened in january 2023. the patients ot the dental health care access center consulting the dental department have largely been treated as dental emergencies. however, to date, no study has been carried out into the nature of these patients' consultations or treatments. this new patient management has necessitated adaptations within the dental department, but there are no data to enable us to better understand and organize the care of these patients. moreover, the cost of dental emergencies has not been estimated. our hypotheses are that patients of the dental health care access center consulted mainly the dental departement for painful emergencies and that the emergency dental cares were provided rapidly and at low cost. on the other hand, patient flow was probably correlated with the days when a social worker of the dental health care access center was present, referring patients to the dental department. the main aim of the study is to describe the nature of emergency dental care provided to patients of the dental health care access center at the dental department of the university hospital of nancy. the secondary objectives are: i) to describe the temporality of dental emergency consultations for patients of the dental health care access center, ii) to describe the rate of dental consultations secondary to an initial emergency consultation, and iii) describe the direct cost of emergency consultations and treatment.

in france, the health care access center are gateway medical and social services for people who need healthcare but have difficulty accessing it due to lack of social protection, living conditions or financial difficulties. they provide access to medical and dental consultations. the development of dental health care access center across france is helping to improve the territorial coverage of primary care services. consultations, diagnostic and treatments are provided free of charge to patients of the health care access center.

Eligibility criteria:
inclusion criteria: * all patients from the dental health care access center who consulted for a dental emergency at the dental department of the university hospital of nancy from 1st january 2023 to 30 june 2024. exclusion criteria: * patient who has objected to the use of his or her medical data

Keywords: dentistry dental care